This morning, the German group revealed that mineralocorticoid receptor antagonist (MRA) Kerendia (finerenone) was able to reduce cardiovascular death and other heart failure events compared to ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for ... It previously filed the drug for this use in the US and China. The submission follows positive ...

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

Does finerenone improve outcomes in patients withheart failure (HF) with mildly reduced or preserved ejection fraction?

Intensifying oral diuretic therapy was linked to worse prognosis, but not everybody is sold on its use an endpoint.

Finerenone has also been submitted for marketing authorization in this common form of heart failure in China, the EU, and the US, and these applications are currently under review. Further regulatory ...

Over a median of 32 months, finerenone significantly reduced the primary endpoint, with 1,083 events in the finerenone group and 1,283 events in the placebo group (rate ratio 0.84; 95% confidence ...